L-Glutamine

L-glutamine has a sharper evidence split than its marketing suggests. The strong, settled use cases are narrow and clinical. The wellness and bodybuilding claims that drive most retail sales are much weaker.

Where the evidence is strongest: sickle cell disease. The Niihara 2018 NEJM phase 3 trial in 230 patients (0.3g/kg twice daily for 48 weeks) found a significant reduction in vaso-occlusive pain crises (median 3.0 vs 4.0, p=0.005) and hospitalizations. This led to FDA approval of Endari, a prescription pharmaceutical-grade oral L-glutamine, in 2017. Endari is a drug, not a consumer supplement. If you have sickle cell disease, talk to your hematologist about Endari, not about buying glutamine powder on Amazon.

Where the evidence is genuinely interesting: post-infectious IBS-D. The Zhou 2019 Gut trial randomized 106 patients with post-infectious diarrhea-predominant IBS to 5g of glutamine three times daily or placebo for 8 weeks. The primary outcome (a 50-point reduction on the IBS Severity Scoring System) was met by 79.6% of glutamine patients vs 5.8% on placebo. That is an unusually large effect size for an IBS trial and the result has not yet been replicated by an independent group, so treat it as a strong early signal rather than settled. The mechanism is plausible: enterocytes (intestinal epithelial cells) use glutamine as their primary fuel and primary substrate for tight junction protein synthesis. Smaller trials in Crohn's disease (Benjamin 2012, glutamine plus whey improved intestinal permeability) hint at the same gut-barrier story but the IBD literature overall is mixed.

Where the evidence is messy: critical care. The 2013 REDOXS trial randomized 1,223 ICU patients to high-dose glutamine (0.35g/kg enterally plus 0.5g/kg parenterally daily) and found a trend toward increased mortality. This was the high-dose, dual-route, sickest-of-the-sick population. Subsequent reviews of parenteral glutamine in more stable surgical and ICU patients (Wischmeyer 2014) found clinical benefits, and oral glutamine in less critically ill patients (post-surgical, burns, short bowel syndrome) has a much better track record. The lesson from REDOXS is not "oral glutamine is dangerous" but "glutamine pharmaconutrition is dose-and-population dependent and should be physician-supervised."

Where the evidence is weak despite decades of marketing: resistance training, muscle protein synthesis, immune function in healthy athletes, and DOMS. Well-controlled trials in healthy lifters (Candow 2001 is the classic null result: 6 weeks of glutamine at 0.9g/kg lean mass added to resistance training did nothing for strength, body composition, or muscle protein degradation vs placebo) have repeatedly failed to find an effect. Gleeson's 2008 J Nutr review concluded that despite a plausible mechanism (heavy training transiently lowers plasma glutamine; glutamine fuels immune cells), supplementation does not actually reduce infection rates or improve recovery in healthy trained athletes. The bodybuilding-supplement industry has been selling glutamine for muscle and recovery for 30 years on data that has not held up. If you are a healthy lifter eating 1.6-2.2g/kg/day of complete protein, you are already consuming several grams of glutamine from food and additional supplementation has shown no benefit.

Honest practical bottom line: if you have post-infectious IBS-D, 5g three times daily for 8 weeks is a reasonable evidence-based trial under physician guidance. If you have sickle cell disease, talk to your doctor about prescription Endari. If you are recovering from major surgery, burns, or have short bowel syndrome, glutamine pharmaconutrition has a real clinical role and your care team should be running it. If you are buying glutamine for gym recovery, muscle building, or immune support during heavy training, the trials do not back up the marketing.